Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment

Core Insights - Clearmind Medicine Inc. has received notice of publication from the China National Intellectual Property Administration for its proprietary non-hallucinogenic compound, 5-methoxy-2-aminoindane (MEAI), aimed at treating depression [1] - Major depressive disorder affects over 280 million people globally and is a leading cause of disability, with limited innovative treatment options available [2] - Preclinical studies indicate that MEAI may enhance mood regulation and reduce anhedonia, providing a differentiated therapeutic approach for patients unresponsive to conventional antidepressants [3] - Clearmind's intellectual property portfolio includes 19 patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property [4] Company Overview - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to address widespread health issues, including alcohol use disorder [4] - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4] - Clearmind's shares are traded on Nasdaq under the symbol "CMND" and on the Frankfurt Stock Exchange under "CWY0" [5]